Imagyn licenses MicroSpan line to Ethicon:
This article was originally published in Clinica
Imagyn Medical Technologies is to license its MicroSpan microhysteroscopy product line to Ethicon. Under the terms of the agreement, which includes cash payments of $4 million with certain milestones, Imagyn, of Newport Beach, California, will initially supply the products to Ethicon for up to two years on an exclusive basis. Ethicon will have a worldwide, exclusive licence to manufacture and market the products for ten years. After this time, Somerville, New Jersey-based Ethicon will own the products. Imagyn recently announced the divestiture of its impotence product lines to Timm Research for $25.8 million. The company is looking at options - including sale or alliances - for its remaining non-strategic assets.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.